Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$147.61
▼ $2.10 (-1.4%)
Market data updated: 09/20 11:00 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$10.49B
Day Range
$146.21 - $150.78
52-Week Range
$122.00 - $200.44
Beta
—
Next Earnings
28.10.2026
Support
$146.20
Resistance
$187.96
ALGN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+11.3% (1Y)
Strengths: 1/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Gross margin
Gross margin: 67.2% — strong
Fundamental
Biggest negative driver
DCF Fair Value
Estimated fair value: $106.91 vs. price $147.61 (-27.6%)
Fair Value
What to watch next
When today echoes the past.
86/100
Similarity
15
Historical Matches
92/100
Analog Quality
-16.9%
Median 40D Outcome
20/100
Pattern Consistency
🟢 Bullish
40%
+7.6% … +14.0%
🟡 Base
0%
— … —
🔴 Bearish
60%
-18.9% … -9.0%
Typical timeframe (based on real historical rates clearing a 60% bar): 20 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 40% (95% CI 20%–64%) saw the stock rise within 20 trading days, with a median gain of -5.9%.
Echo #1 — Oversold Reversal
7 occurrence(s) · 57% historical success
Echo #2 — Momentum Breakout
1 occurrence(s) · 0% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 53% (30%–75%) | +2.4% | -3.6% … +5.2% | +0.5% |
| 10D | 47% (25%–70%) | +0.0% | -4.9% … +6.2% | +0.9% |
| 20D | 40% (20%–64%) | -5.9% | -12.1% … +9.0% | +1.9% |
| 40D | 27% (11%–52%) | -16.9% | -32.1% … +1.7% | +1.7% |
| 60D | 20% (7%–45%) | -15.9% | -22.4% … -5.1% | +2.3% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2023-05-31 | 86/100 | Consolidation | +20.9% | +26.1% |
| 2023-10-10 | 85/100 | ✓ Downtrend | -31.1% | -7.6% |
| 2024-04-15 | 83/100 | Consolidation | -10.5% | -15.9% |
| 2020-02-03 | 82/100 | Consolidation | -11.2% | -12.8% |
| 2026-06-03 | 82/100 | Consolidation | +14.1% | -2.6% |
| 2023-09-19 | 82/100 | Consolidation | -13.0% | -27.2% |
| 2019-05-30 | 82/100 | Consolidation | -9.0% | -41.0% |
| 2019-06-24 | 82/100 | Consolidation | -3.3% | -37.7% |
| 2019-07-23 | 80/100 | Consolidation | -36.1% | -22.5% |
| 2024-12-27 | 80/100 | ✓ Downtrend | +6.2% | -22.3% |
| 2021-12-03 | 80/100 | Consolidation | +4.6% | -19.9% |
| 2021-10-25 | 79/100 | Downtrend | +13.5% | -16.8% |
| 2023-10-24 | 78/100 | ✓ Downtrend | -18.9% | +2.3% |
| 2024-05-30 | 78/100 | Downtrend | -5.9% | -9.7% |
| 2026-05-19 | 78/100 | Consolidation | +11.8% | +16.9% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
36
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
25d ago · $160.46
Evidence: 1 bullish / 9 bearish technical signals agreeing
What happened after
26d ago · $159.64
Evidence: 1 bullish / 9 bearish technical signals agreeing
What happened after
27d ago · $162.55
Evidence: 1 bullish / 8 bearish technical signals agreeing
What happened after
28d ago · $162.55
Evidence: 1 bullish / 8 bearish technical signals agreeing
What happened after
29d ago · $162.55
Evidence: 1 bullish / 9 bearish technical signals agreeing
What happened after
31d ago · $165.52
Evidence: המניה במגמת ירידה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
31d ago · $165.52
Evidence: 2 bullish / 6 bearish technical signals agreeing
What happened after
32d ago · $167.91
Evidence: -6.8pp vs. sector average today
What happened after
32d ago · $169.68
Evidence: 3 bullish / 5 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 18, 2026
Then
52
$169.71
Now
36
$147.61
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
42
Quality
42
Value
38
Momentum
9
Risk
42
Sentiment
26
Fundamental
64
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING ALGN...
Recent media coverage of Align Technology has centered on its stock valuation and leadership changes. Analysts debate whether its shares, down over 50% in five years, may now be undervalued despite mixed earnings guidance and sector pressures. The company recently added Quentin Blackford to its board while Andrea Saia, a long-time director, resigned, signaling shifts in strategy and governance amid its role as a leader in digital dentistry. Earnings reports met expectations but included cautious future outlook, contributing to recent stock volatility.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Align Technology. News trend score: 26. Reason: 10 of the last 20 articles are negative, versus 6 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
36
Psychology
81
Fundamentals
64
Technical
9
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The price rise has far outpaced the actual improvement in fundamental data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
-19%
Market Narrative
41
Fundamental Reality
36
Narrative Gap
+5
🧠 StockIQ Psychologist
The market behavior for ALGN suggests a dominant anchoring bias, likely due to its near-term proximity to support (1.3% above). The narrative gap (16) hints at a disconnect where perceived value (52) exceeds observable fundamentals (36), but this is tempered by negative momentum and subdued volume. Overconfidence (39) and loss aversion (42) coexist, reflecting conflicting signals: price premiums (+43% DCF) versus underperformance (-2.3% ROC). The key open question is whether traders will hold near support or pivot based on new catalysts, given muted panic or FOMO signals. Herding (48) indicates relative underperformance awareness, but not urgency.
Updated: 09/09/2026, 02:59 PM
What could change this?
👥 What the crowd believes
"Align Technology stock has delivered a steeply negative 5 year share price performance, yet current valuation checks suggest the market price may now be below what its cash flows imply."
"Align Technology’s recent guidance weighed on sentiment, and the stock has fallen about 12% since the earnings release."
"Align Technology appoints Quentin Blackford... introduces new operating and strategy experience as Align Technology marks the end of Saia's long tenure."
"Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Align Technology (NASDAQ:ALGN) and its peers."
📈 16D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 96/100
🔴 Weakest match
Peter Lynch — 6/100
🗣️ Why do they disagree?
The stark divide in verdicts for ALGN reflects deep methodological disagreements about risk, valuation, and market psychology. Samuel Armstrong Nelson and Charles Mackay’s high scores suggest a favorable cycle position and absence of crowd-driven euphoria, while Howard Marks (both cycle and general) sees it as a mid-cycle opportunity—all signaling a cautious optimism. In contrast, the lowest scores—from Graham, Lynch, and Housel—reveal a consensus that the stock lacks the defensive strength, growth-at-a-reasonable-price justification, or volatility tolerance required by their frameworks. Meanwhile, the middle tier (like Schwager’s neutral stance or Veblen’s mixed growth signal) highlights uncertainty over whether the company’s fundamentals justify its valuation, with some questioning whether growth translates into sustainable profits. The clash between cyclical bulls and contrarian skeptics underscores whether ALGN is a speculative bet or a fundamentally sound investment.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 95
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 89
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 69
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 46
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 36
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 32
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 22
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 18
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 17
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 13
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 9
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 8
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 6
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
67.2%
Operating Margin
13.5%
Net Margin
10.2%
EBITDA Margin
19.4%
ROE
10.1%
ROA
6.6%
ROIC
—
EPS
$5.66
Cash
$1.09B
Total Debt
—
Current Ratio
1.36
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$147.61
Estimated Fair Value (DCF)
$106.91
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-27.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
2.6%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 2.6% | $503.63M | $462.05M |
| 2 | 2.6% | $516.67M | $434.87M |
| 3 | 2.6% | $529.90M | $409.18M |
| 4 | 2.5% | $543.30M | $384.89M |
| 5 | 2.5% | $556.88M | $361.94M |
Base FCF (last actual year)
$490.78M
Terminal Value
$8.78B
Present Value of Terminal Value
$5.71B
Enterprise Value
$7.76B
Net Debt
$0
Equity Value
$7.76B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$55.78
Tangible Book Value per Share (Tangible NAV)
$47.71
Sentiment based on basic keywords (not AI) — 6 positive, 4 neutral, 10 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 9.9.2026
StockStory · 9.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 8.9.2026
Yahoo · 7.9.2026
Yahoo · 6.9.2026
Simply Wall St. · 6.9.2026
Yahoo · 6.9.2026
Simply Wall St. · 6.9.2026
Yahoo · 5.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 4.9.2026
StockStory · 4.9.2026
Align Technology (ALGN) currently has a StockIQ AI score of 36/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ALGN currently scores 36/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ALGN's estimated fair value is $106.91, which is 27.6% below the current price of $147.61. This is one valuation model among several signals in the fair-value category, not a price target.
ALGN's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Gross margin: 67.2% — strong.
Based on the real signals StockIQ computed: Estimated fair value: $106.91 vs. price $147.61 (-27.6%); Operating margin is eroding over time; Calmar: -0.36 (3y annualized return -22.6% / max drawdown 62.2%).
StockIQ has no recorded dividend payment history for ALGN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Blackford Quentin S. | Grant/Award from Employer | 27.8.2026 | 1,376 | +1,376 | — |
| Blackford Quentin S. | Grant/Award from Employer | 27.8.2026 | 1,376 | +1,376 | — |
| MORROW GEORGE J | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| LARKIN C RAYMOND JR | Exercise of Derivative Securities | 20.5.2026 | 2,326 | +2,326 | — |
| LACOB JOSEPH | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| Dallas Kevin J | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| Vitalone Britt J. | Exercise of Derivative Securities | 20.5.2026 | 1,443 | -1,443 | — |
| Myong Anne | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| Vitalone Britt J. | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| SIEGEL SUSAN E | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| Poul Mojdeh | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| LACOB JOSEPH | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| LACOB JOSEPH | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| Conroy Kevin T | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| Poul Mojdeh | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| MORROW GEORGE J | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| Conroy Kevin T | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| Dallas Kevin J | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| Dallas Kevin J | Exercise of Derivative Securities | 20.5.2026 | 1,745 | -1,745 | — |
| Vitalone Britt J. | Exercise of Derivative Securities | 20.5.2026 | 1,443 | +1,443 | — |
| Conroy Kevin T | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| SIEGEL SUSAN E | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
| LARKIN C RAYMOND JR | Grant/Award from Employer | 20.5.2026 | 2,448 | +2,448 | — |
| Poul Mojdeh | Grant/Award from Employer | 20.5.2026 | 1,836 | +1,836 | — |
| Myong Anne | Exercise of Derivative Securities | 20.5.2026 | 1,745 | +1,745 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,856,413 shares short as of 2026-08-31 · vs. 4,202,287 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
68.0% of trading volume this week was short selling, vs. 67.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology